Here at HB Biotech, where our mandate is to invest in listed drug and device companies with market capitalisation less than US$5b at initial investment, there have been few opportunities to invest in ...
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
On Wednesday the U.S. Department of Commerce announced it would implement new export controls on certain biotechnology equipment, citing national security concerns relating to artificial ...
WASHINGTON, Jan 15 (Reuters) - The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security ...
As 2025 begins, emerging biotechnology firms can be sorted into two groups: haves and have-nots. Venture funding rose last year, but a good portion of that money was concentrated into nine-figure ...
The J.P. Morgan Healthcare Conference in San Francisco is back for 2025 and here at Fierce Biotech, we’re going to bring you all the latest updates live from the life sciences event of the year.
CEO Surbhi Sarna's small team at Collate so far includes founding chief architect Jigish Patel and cofounder and CTO Nate Smith. Surbhi Sarna sold her last startup, nVision Medical, for $275 ...
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its ...
This week at the 43rd J.P. Morgan Healthcare Conference, Pops will be touting Alkermes’ rare set of attributes as a self-funded neuroscience biotech ... “The theme for this year [at J.P ...
Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical company said, marking the biggest biotech buyout in more than a year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback